• A shortage of hospital pharmacists is on the horizon, leaders say

    As applications for pharmacy schools and residency programs wither, hospital pharmacy leaders are warily preparing for a shortage of clinical pharmacists. 
  • How does your system manage rare disease patients? Becker's wants to hear.

    Fill out this short survey here and attend our annual meeting for free.
  • Health systems plunge into home infusion service lines

    Despite financial headwinds, the healthcare industry is plugging money and resources into home infusion service lines, according to Provident Healthcare Partners.
  • FDA approves 1st Chikungunya virus vaccine

    The FDA on Nov. 9 granted approval to Ixchiq, the first vaccine to protect against chikungunya virus. 
  • Walgreens chief medical officer exits

    The chief medical officer of Walgreens Boots Alliance, Kevin Ban, MD, will exit his role as of Nov. 10, a spokesperson confirmed to Becker's.
  • Walgreens to lay off 5% of corporate staff

    Walgreens is planning to lay off about 5% of its corporate workforce, or 267 employees, the Chicago Tribune reported Nov. 9.
  • 5 growth areas for health system pharmacy leaders: McKinsey

    Hospital and health system pharmacy leaders might be missing out on big-picture goals in "emerging frontiers" as they extinguish long-standing issues, such as rising healthcare costs and a pharmacy technician shortage, according to an Oct. 7 article from McKinsey. 
  • Postpartum depression drug may cost some nearly $16K out of pocket

    Shelling out nearly $16,000 for a 14-day course of medication is what to expect for the wholesale cost of Zurzuvae, the first oral treatment for postpartum depression, according to a Nov. 7 news release from drugmaker Sage Therapeutics. 
  • Retail pharmacy walkout organizers push for unionization

    After a three-day walkout of retail pharmacy employees across the U.S., organizers of the grassroots labor action created an organization that seeks to unionize the workforce and advocate for safer working conditions. 
  • Cancer drugs: 4 things to know

    As 2023 entered its fourth quarter, one cancer drug shortage resolved as more than a dozen continue; a California system helped make a chemotherapy management app; and the FDA approved a new head and neck cancer medication. 
  • FDA approves new weight loss drug

    On Nov. 8, the FDA approved Eli Lilly's Zepbound (tirzepatide), a weekly injection for chronic weight management. 
  • Accord Healthcare resumes making methotrexate

    Accord Healthcare, a London-based drugmaker, resumed manufacturing of two methotrexate solutions, according to a Nov. 7 update from the FDA. 
  • FDA probes hospitalizations tied to fake Ozempic

    The FDA is investigating reports of hospitalizations tied to suspected counterfeit versions of semaglutide drugs, including three in the U.S., according to records from the agency's adverse event reporting system. 
  • Kaiser calls union's ask of 43% raise 'not reasonable'

    As hundreds of pharmacy and imaging workers for Kaiser Permanente strike, a spokesperson for the system told CBS affiliate KPIC their union's ask for a 43% raise over the next four years is "frankly, not reasonable."
  • 2nd choice drug reduced C. diff infections by 45%

    Pneumonia patients who took an antibiotic that's typically reserved as an alternative were less likely to develop Clostridioides difficile infections compared to those taking the recommended drug, according to a study from Veterans Affairs Hospitals. 
  • Pharmacists treating hypertension patients could save US $1.1 trillion: Study

    The U.S. healthcare industry could save more than $1.1 trillion and prevent about 15 million heart attacks over the next 30 years if pharmacists were more involved in hypertension care, according to research conducted by Virginia Commonwealth University in Richmond. 
  • 340B Health, ASHP chide CMS' final payment rules

    Organizations representing thousands of hospital pharmacies are criticizing CMS' plan to not provide further reimbursement to 340B hospitals after paying a $9 billion lump sum. 
  • FDA puts clinical hold on cancer drug study

    Nurix Therapeutics, a drugmaker based in San Francisco, said the FDA has placed a partial clinical hold on its phase 1 trial for an experimental drug for lymphoma and leukemia. 
  • The pharmacists who revealed the myth of 'decongestants'

    Sixteen years after pharmacists from the University of Florida College of Pharmacy in Gainesville petitioned the FDA to require new efficacy studies of an ingredient in decongestants, their efforts came to fruition. In September, an FDA panel unanimously declared the ingredient ineffective. 
  • Intermountain pushes into drone drug delivery

    Salt Lake City-based Intermountain Health is one of the latest health systems to enter the emerging world of prescription delivery via drone. 
  • Phase 3 drug study finds 'unprecedented' positive results

    A global study of zoliflodacin, a drug candidate for gonorrhea, found "unprecedented" phase 3 results, its drugmaker said Nov. 1. 

Featured Whitepapers

Featured Webinars